Frontiers reaches 6.4 on Journal Impact Factors
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
Frontiers in Bioengineering and Biotechnology is a member of the Committee on Publication Ethics.
Short Name: Front. Bioeng. Biotechnol.
Electronic ISSN: 2296-4185
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Semantic Scholar, Ulrich's Periodicals Directory, CLOCKSS, EI Compendex, OpenAIRE, Zetoc
PMCID: all published articles receive a PMCID
Frontiers in Bioengineering and Biotechnology is composed of the following Specialty Sections:
The specialty sections of Frontiers in Bioengineering and Biotechnology welcome submission of the following article types: Book Review, Case Report, Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Protocols, Review, Specialty Grand Challenge, Systematic Review, Technology Report, Code and Policy Brief.
When submitting a manuscript to Frontiers in Bioengineering and Biotechnology, authors must submit the material directly to one of the specialty sections. Manuscripts are peer-reviewed by the Associate and Review Editors of the respective specialty section.
Articles published in the specialty sections above will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in the Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Bioengineering and Biotechnology.